Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$38.80 +1.6%	$36.73	$23.42 ▼ $62.58	$2.25B	0.8	706,919 shs	722,567 shs
DNLI Denali Therapeutics	$15.49 +1.7%	$14.29	$10.57 ▼ $33.33	$2.26B	1.36	1.42 million shs	2.74 million shs
GLPG Galapagos	$32.00 +0.3%	$30.60	$22.36 ▼ $33.86	$2.11B	0.1	329,164 shs	161,129 shs
SAGE Sage Therapeutics	$8.68	$8.90	$4.62 ▼ $11.44	$543.54M	0.26	3.63 million shs	N/A

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	+3.75%	+4.14%	-3.68%	+28.19%	-18.90%
DNLI Denali Therapeutics	+4.96%	+5.33%	+9.81%	+13.49%	-39.08%
GLPG Galapagos	+0.50%	+0.41%	-2.62%	+11.10%	+26.57%
SAGE Sage Therapeutics	0.00%	0.00%	-0.80%	+32.92%	+0.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.3577 of 5 stars	3.4	2.0	4.3	2.7	0.8	1.9
DNLI Denali Therapeutics	4.204 of 5 stars	3.6	1.0	4.7	3.0	3.3	0.0
GLPG Galapagos	0.133 of 5 stars	0.7	2.0	0.0	0.6	0.0	0.6
SAGE Sage Therapeutics	3.474 of 5 stars	2.0	5.0	4.1	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.75	Moderate Buy	$56.33	45.19% Upside
DNLI Denali Therapeutics	3.12	Buy	$33.62	117.01% Upside
GLPG Galapagos	1.38	Strong Sell	$25.33	-20.83% Downside
SAGE Sage Therapeutics	1.93	Reduce	$7.85	-9.56% Downside

Current Analyst Ratings Breakdown

Latest SAGE, AGIO, DNLI, and GLPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	DNLI Denali Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$33.00 ➝ $30.00
8/5/2025	GLPG Galapagos	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Sell
7/28/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$71.00 ➝ $65.00
7/28/2025	DNLI Denali Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/22/2025	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $51.00
7/8/2025	SAGE Sage Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00 ➝ $9.20
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	61.76	N/A	N/A	$23.57 per share	1.65
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	$7.02 per share	N/A
GLPG Galapagos	$275.61M	7.65	$0.73 per share	43.74	$47.57 per share	0.67
SAGE Sage Therapeutics	$41.24M	13.18	N/A	N/A	$5.89 per share	1.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.00	3.53	N/A	N/A	1,590.42%	-3.49%	-3.23%	10/30/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.80	N/A	N/A	N/A	N/A	-40.79%	-36.39%	11/5/2025 (Estimated)
GLPG Galapagos	$80.16M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	10/22/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$4.89	N/A	N/A	N/A	-427.78%	-67.10%	-58.42%	11/4/2025 (Estimated)

Latest SAGE, AGIO, DNLI, and GLPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	DNLI Denali Therapeutics	-$0.74	-$0.72	+$0.02	-$0.72	$5.64 million	N/A
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	-$1.93	-$0.19	-$1.93	$9.46 million	$12.50 million
7/30/2025	Q2 2025	SAGE Sage Therapeutics	-$0.96	-$0.79	+$0.17	-$0.79	$16.69 million	$31.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
GLPG Galapagos	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.48	14.04
DNLI Denali Therapeutics	0.01	10.27	10.27
GLPG Galapagos	N/A	8.08	7.99
SAGE Sage Therapeutics	N/A	9.16	9.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
DNLI Denali Therapeutics	92.92%
GLPG Galapagos	32.46%
SAGE Sage Therapeutics	99.22%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
DNLI Denali Therapeutics	12.50%
GLPG Galapagos	2.91%
SAGE Sage Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	58.10 million	55.60 million	Optionable
DNLI Denali Therapeutics	430	146.21 million	127.94 million	Optionable
GLPG Galapagos	1,310	65.90 million	N/A	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable

SAGE, AGIO, DNLI, and GLPG Headlines

Recent News About These Companies

Reunion’s psychedelic drug headed to late-stage testing

August 18, 2025 | yahoo.com

Why Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today

August 6, 2025 | finance.yahoo.com

GSA Capital Partners LLP Increases Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

August 5, 2025 | marketbeat.com

Federated Hermes Inc. Increases Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

August 3, 2025 | marketbeat.com

Wall Street Zen Upgrades Sage Therapeutics (NASDAQ:SAGE) to Hold

August 2, 2025 | marketbeat.com

Sage (SAGE) Q2 Revenue Jumps 264%

August 1, 2025 | aol.comA

Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics

August 1, 2025 | finance.yahoo.com

Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Rating of "Reduce" from Brokerages

July 31, 2025 | marketbeat.com

Sage Therapeutics Announces Second Quarter 2025 Financial Results

July 31, 2025 | finance.yahoo.com

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates

July 30, 2025 | zacks.com

Sage Therapeutics (NASDAQ:SAGE) Sees Strong Trading Volume - Time to Buy?

July 30, 2025 | marketbeat.com

Monaco Asset Management SAM Takes $3.51 Million Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)

July 30, 2025 | marketbeat.com

Cerity Partners LLC Purchases New Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)

July 27, 2025 | marketbeat.com

BML Capital Management LLC Buys New Shares in Sage Therapeutics, Inc. (NASDAQ:SAGE)

July 26, 2025 | marketbeat.com

Europe's CHMP gives thumbs up to Lilly's Kisunla and Gilead's long-acting PrEP drug Yeytuo

July 25, 2025 | fiercepharma.comF

Cwm LLC Acquires 58,410 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

July 25, 2025 | marketbeat.com

Sage Therapeutics (SAGE) Expected to Announce Earnings on Wednesday

July 23, 2025 | marketbeat.com

Sage Therapeutics (NASDAQ:SAGE) Sees Large Volume Increase - What's Next?

July 22, 2025 | marketbeat.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

July 14, 2025 | businesswire.com

Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock

July 9, 2025 | nasdaq.com

Scotiabank Downgrades Sage Therapeutics (SAGE)

July 9, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SAGE, AGIO, DNLI, and GLPG Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$38.80 +0.60 (+1.57%)

Closing price 04:00 PM Eastern

Extended Trading

$38.81 +0.01 (+0.02%)

As of 05:51 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Denali Therapeutics NASDAQ:DNLI

$15.49 +0.26 (+1.71%)

Closing price 04:00 PM Eastern

Extended Trading

$15.56 +0.07 (+0.48%)

As of 06:52 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Galapagos NASDAQ:GLPG

$32.00 +0.08 (+0.25%)

Closing price 04:00 PM Eastern

Extended Trading

$32.55 +0.55 (+1.72%)

As of 05:06 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Sage Therapeutics NASDAQ:SAGE

$8.68 0.00 (0.00%)

As of 07/31/2025

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time